We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.10 | 0.35% | 28.60 | 28.20 | 29.00 | 28.75 | 28.60 | 28.75 | 450,812 | 13:07:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 48.48M | -776k | -0.0011 | -260.00 | 193.07M |
Date | Subject | Author | Discuss |
---|---|---|---|
30/11/2018 15:46 | There she goes 35p next if Mr 10k keeps buys today | sparky333 | |
30/11/2018 15:39 | 31p to buy soon. Get in quick this has legs | sparky333 | |
30/11/2018 15:35 | Snap back to 60p very quickly in no news. | sparky333 | |
30/11/2018 15:34 | Topped up.Rude not to!!!! | billthebank | |
30/11/2018 15:31 | A dozen 10k buys in last hour | billthebank | |
30/11/2018 15:21 | Just the beginning all the way to one pound!!!! | billthebank | |
30/11/2018 15:08 | Nice rise for a friday afternoon, glad I bought a few at 25p earlier in the week :-) | azuli | |
28/11/2018 11:34 | A wee rise like this every day till Xmas will do just fine | billthebank | |
28/11/2018 06:37 | no it was a reflection of the dodgy shareprice action and pointing out the fact no one at the company is buying shares, just exercising a few cheapo options | mister md | |
27/11/2018 23:01 | As Berny said, it's not the act of buying and selling, it's the subsequent writing of negative comments everyone you sell that is scummy. | discojames | |
27/11/2018 21:08 | and when you see big sell at 20p followed by 50% rally to 30p you take some profits if you are trading | mister md | |
27/11/2018 21:00 | to quote Buffett rule #1 dont lose money rule #2 dont forget rule #1 bernymadoff your hero by any chance? | mister md | |
27/11/2018 20:12 | hardly gloating was it mon ami ? On a share like this I was happy with a 10% gain - might sell this current lot at your 50p+ average though. I like to buy and hold decent companies but occassionally trade dodgy Aim stuff like this one. The price activity here has been shocking and still intrigued by the massive sells at 20p | mister md | |
27/11/2018 20:02 | People like you make me sick. Yesterday afternoon you were gloating over the fact that it had given up some of its gains from Friday. Here's what you wrote: "Hope everyone took their profits on the 23p shares from Friday ? I see the directors are all piling in to add to their tiny holdings ... or not ?" Well your alleged buy price is not far off 23p and the directors haven't bought any shares. So what's with the volte face? Don't mind people trading stocks but when they resort to deramping and trying to spook people into selling to get themselves a cheaper entry it really does take the biscuit. | bernymadoff | |
27/11/2018 18:52 | back in with a few at 25p. Supply seems tight again. Nice 50k buy reported after close | mister md | |
27/11/2018 18:01 | Thanks Mike for the update and lets hope the company does well not only for shareholders but jobs/economy in this brexit climate!! | joeblogg2 | |
27/11/2018 17:46 | Joe. As always buyer beware. Having said that, there are some fundamentals that look really good here. Essentially Hvivo is a service company providing testing facilities to big pharmaceuticals. They also have a couple of historical products in their portfolio through a joint venture with strong results so far. As a service company alone (which is their focus) they've recently won contracts and are looking to reduce costs and return to profitability next year. AIM companies that do this also do best on AIM. If the management stick to their vision then we should see something me real growth here. I'd expect the share price to yo-yo a bit as the short term investors buy and sell and take profit, probably in the 30s, and some mid term investors do the same around the 50 to 70 mark. After that long term investors will be looking at the £s. We're benefiting from a lack of shares in private investor hands at the moment and have just seen a sell off by a small institutional investor which has driven the price artificially low. A good time to buy, in my opinion. Any other thoughts anyone? | mikelmas10 | |
27/11/2018 16:11 | Tried to pick up a few of these yesterday but I couldn't get an online quote at the time. Picked up £5k's worth today instead, the 19,333 is my buy. | azuli | |
27/11/2018 16:03 | Lots of new posters on here which is nice to see as it signals a return of positive sentiment and interest in the stock. For their benefit this is the reason I'm invested here. There is the very real prospect of a major pharma paying a huge amount for Flu-v and maybe even the Ags-v anti malaria vaccine. Plenty of examples of Biotechs selling P3 ready drugs following successful P2 for big money. hxxps://www.fiercebi Yes you're reading it right. It's a $800m upfront payment with $400m milestones and double digit royalties. And this is for a drug targeting a market size forecast to be £8.7bn by 2025. In contrast the market size for flu vaccines is expected to be $11.4bn by 2025. Here's another example of a successful P2 drug being bought out by big pharma for mega bucks. hxxp://www.bioworld. The market for Crohn's Disease is substantially smaller at $4.7bn by 2025 but Nogra still got a $710m upfront payment. Of course these deals take time to negotiate and many if not most PIs don't have the patience or the research background to hold for the best part of a year. I've been adding down here and have now accumulated a handsome six figure holding. Our CEO and the CEO of Imutex both have illustrious backgrounds which are both ideal for negotiating a great deal.and I have every confidence that in time they will deliver. Gregory Stoloff is a former investment banker who was responsible for arranging project finance for the major pharmas. HVO's CEO has formerly been Chief Operations Officer of a FTSE 250 company. The macro climate is also favourable with governments and public health organisations throwing tens of millions of dollars into finding a universal flu vaccine. The seller/shorter has provided an unexpected and once in a lifetime opportunity to get in at lows. Don't stare a gift horse in the mouth. | bernymadoff | |
27/11/2018 15:33 | let's hope they say something new that day then! | qs99 | |
27/11/2018 14:51 | updated company ATTENDING world vaccine and immunotherapy congress | fromthesidelines | |
27/11/2018 14:44 | company presenting in San Diego 28th to 30th November per website | fromthesidelines | |
27/11/2018 14:41 | Welcome Joe, I think this is incredibly low risk at this price. Even our resident derampers can;t highlight any form of risk here. "Huge" number of contract negotiations happening at the moment and lots of cash in the bank, so no risk of a placement - what else is there to worry about? | discojames |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions